Evidence map›Paper›PMID 41638576›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2026

Elevated T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Expression and Immune Cell Dysfunction Characterize Complex Proteins Associated With SET1 (COMPASS)-Like Complex Gene-Mutated Pancreatic Ductal Adenocarcinoma (PDAC).

Shungang Zhang, Elaina R Daniels, Jake McGue, Ranga Sudharshan, Hongsun C Kim, Dafydd G Thomas, Santhoshi Krishnan, Timothy L Frankel, Erika Hissong, Arvind Rao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shungang ZhangDepartment of Pathology & Clinical Labs, University of Michigan, Ann Arbor, Michigan.
Elaina R DanielsDepartment of Pathology & Clinical Labs, University of Michigan, Ann Arbor, Michigan.
Jake McGueDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.
Ranga SudharshanDepartment of Computational Medicine and Bioinformatics, Radiation Oncology, and Biostatistics, University of Michigan, Ann Arbor, Michigan.
Hongsun C KimDepartment of Pathology & Clinical Labs, University of Michigan, Ann Arbor, Michigan.
Dafydd G ThomasDepartment of Pathology & Clinical Labs, University of Michigan, Ann Arbor, Michigan.
Santhoshi KrishnanDepartment of Computational Medicine and Bioinformatics, Radiation Oncology, and Biostatistics, University of Michigan, Ann Arbor, Michigan.
Timothy L FrankelDepartment of Surgery, University of Michigan, Ann Arbor, Michigan.
Erika HissongDepartment of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill-Cornell Medicine, New York, New York.
Arvind RaoDepartment of Computational Medicine and Bioinformatics, Radiation Oncology, and Biostatistics, University of Michigan, Ann Arbor, Michigan.
Naziheh AssarzadeganDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida.
Jiaqi ShiDepartment of Pathology & Clinical Labs, University of Michigan, Ann Arbor, Michigan. Electronic address: jiaqis@umich.edu.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Synthesizing Image-derived Heterogeneity with Genomic measurements for Assessing Disease Aggressiveness in Lower Grade GliomasR37CA214955 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURTEK, SEBASTIAN, RAO, ARVIND · 2018 to 2024
$3.9M
Defining epigenetic signaling to reshape pancreatic tumor microenvironmentR37CA262209 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiaqi Shi · 2022 to 2026
$2.3M
NCI NIH HHS P30 CA046592NCI NIH HHS R37 CA214955NCI NIH HHS R37 CA262209NIH HHS P30CA046592NIH HHS R37CA214955
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to immune therapies. Limited biomarkers, such as mismatch repair proteins, have been used to identify those who may respond to immunotherapy. We identified a subset of aggressive PDACs (⁓25%) carrying mutations in the complex of proteins associated with SET1-like complex genes (CLCGs), which can be used as new biomarkers for targeted immunotherapy. In this study, we compared the immune microenvironment of PDACs harboring CLCG mutations with matched wild-type PDACs using multiplex fluorescent immunohistochemistry and computational imaging techniques. We observed that CLCG-mutant PDACs were infiltrated with fewer CD4

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalPancreatic NeoplasmsReceptors, ImmunologicCD4-Positive T-LymphocytesFemaleHumansLymphocytes, Tumor-InfiltratingMutationTumor MicroenvironmentBiomarkers, TumorReceptors, ImmunologicTIGIT protein, humanCD4(+) T cellsepigenetic regulationimmunosuppressionpancreatic ductal adenocarcinomatumor microenvironment

Identifiers

PMID41638576
PMCPMC13077644

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.